布地奈德/福莫特罗吸入剂对支气管扩张症患者NF-κB通路的影响以及疗效分析

Effect of Budesonide and Formoterol Fumarate Powder for Inhalation on NF-kappa B pathway in patients with bronchiectasis and its efficacy

目的:观察布地奈德/福莫特罗吸入剂长期使用对支气管扩张症患者临床疗效以及NF-κB通路的影响。方法:选取2016-02—2017-12期间我院治疗的支气管扩张症患者142例,随机分为对照组或观察组,每组71例。对照组常规治疗,观察组加用地奈德/福莫特罗吸入剂,1吸/次,2次/d,疗程12周。比较两组临床疗效和不良反应。结果:治疗前两组诱导痰液中p65、IL-6、TNF-α炎性因子表达和FEV1/FVC、FVE1/pred肺功能指标差异无统计学意义(P>0.05),观察组12周疗程结束后p65、IL-6和TNF-α表达显著低于对照组(P<0.01),FEV1/FVC和FVE1/pred显著高于对照组(P<0.05)。对照组临床治疗有效率为76.06%(54/71),显著低于观察组的91.55%(65/71)(P<0.05)。对照组复发率为22.58%(14/62)显著高于观察组的8.06%(5/62)。治疗期间观察组急性加重(1.58±0.27)次,显著低于对照组的(2.14±0.46)次(P<0.05)。对照组不良反应发生率为7.04%(5/71),观察组不良反应发生率为8.45%(6/71),两组不良反应发生率无显著性差异(P>0.05)。结论:布地奈德福莫特罗粉吸入剂长期使用可以抑制支气管扩张症患者NF-κB通路,降低气道局部炎症反应,减少急性加重次数,疗效显著,使用安全。

Objective：To observe the effect ofBudesonide and FormoterolFumarate Powder for Inhalation on NF-kappa B pathway in patients with bronchiectasis and its efficacy.Method：One hundred and forty-two patients were selected in this study.Patients were divided into：control group（n=71）and observation group（n=71）.The control group：conventional therapy.The observation：on the basis of the control group,Budesonide and FormoterolFumarate Powder for Inhalation（2 times/d）was used for 12 weeks.The clinical efficacy and adverse reactions rate was compared.Result：Before treatment,p65,IL-6,TNF-α,FEV1/FVC,and FVE1/predwas no significant difference between the two groups（P〉0.05）.After treatment,p65,TNF-α,and IL-6 expression in observation group weresignificantly lower than thosein control group（P〈0.01）,and FEV1/FVC and FVE1/pred in observation group weresignificantly higher than thosein control group（P〈0.05）.The clinic effective rate in control was76.06%（54/71）which was lower than that of 91.55%（65/71）in observation group（P〈0.05）.The acute exacerbation times in observation group was 1.58±0.27,which was significantly lower than that of 2.14±0.46 in control group（P〈0.05）.The adverse reactions rate was 7.04%（5/71）in control group and 8.45%（6/71）in observation group.There was no significant difference between the two groups（P〉0.05）.Conclusion：Budesonide and FormoterolFumarate Powder for Inhalation can inhibitNF-κB path wayto reduce airway inflammation and times of acute exacerbation,with significant effect and safety.